

Workshop on AB-NCT
October 15th, 16th 2015
Grenoble (France)

More than 56 participants

We would like to thank:

- Jocelyne Riffault
- GDR MI2B
- Labex Primes
- France-Hadron

Some conclusions....

W. Sauerwein, D. Dauvergne and D. Santos

- There are clinical data proving that BNCT has an impact on tumors in human patients and may offer a new approach to treat tumor situation that actually cannot be treated (for example recurrent head and neck cancer after high dose radiotherapy)

- The problem today (10/2015) is that there are not enough neutron sources available to perform the clinical trials necessary to prove evidence
- Worse: there is no neutron source at all in Europe to support such research
- In Japan there are major efforts to install accelerator based BNCT facilities in hospitals, clinical trials are already progressing
- It is overdue to start similar efforts in Europe

AB-NCT in France

- 1- Technical validation of the « ensemble »
(ion source + accelerator + targets + BSAs + neutron and gamma detectors)
IPHI (Saclay) ? , Ganil ?+ targets (LPSC) + detectors (LPSC)
- 2- Physicians, Biologists and Chemists need to join the collaboration.
- 3- Safety regulation needs to be integrated.
- 4- Pre-clinical demonstrator needs to be defined after the technical validation.

An European strategy

- The scientist from different disciplines in Europe, who are interested in BNCT are invited to join a “EU BNCT Team” to bundle efforts for neutron sources that are suitable to perform clinical trials and basic research

